Lost Password? No account yet? Register

Advertisement

New Media Advertisement
Govt research labs develop 28 new drugs for chronic ailments PDF Print E-mail
User Rating: / 0
PoorBest 

The government agencies and institutions like DST, DBT, AYUSH, ICMR and CSIR have developed 28 new molecules targeting chronic diseases like blood pressure, diabetics, gastric ulcer and asthma.

The new molecules also include herbal medicines with a view to ensure cost effective therapy to the people as the country is fast turning into a hub of chronic diseases. This was disclosed in the action taken report on the recommendations by the Parliamentary Standing Committee on Science and Technology on drugs and pharmaceutical research programme. The panel, headed by Dr V Maitreyan, submitted the report recently.

The Indian Council of Medial Research (ICMR) has set up its research priority on all relevant diseases which include both communicable as well as life style chronic diseases. The Council is also interacting with a number of industries and international agencies with regard to access of drugs to the economically weaker sections of the society of the country, the panel was informed.

CSIR laboratories are working on programmes on new drug development for life style diseases such as diabetes, stroke, thrombosis, dyslipidemia, stress, gastric ulcer, dementia etc. A programme on diabetes mellitus will be specifically initiated during the 11th Plan.

DBT has supported various R&D (Multi-centric interactive) projects for chronic diseases and life style disorders such as cancer, cardiothoracic disorder, diabetes, neurological joint disease etc. The department has also taken up an initiative to start clinical trial using Curcumin for various cancers such as oral pre-cancerous lesions, head and neck cancer and cervical cancer.

Diseases like Malaria, Filaria, Urinary problems, Memory disorders and health problems commonly affecting poor people are included in the list of gap areas identified for research and development of Ayurvedic medicines under Golden Triangle Partnership (GTP) scheme of AYUSH.

Drug development for common parasitic diseases and microbial infections covering malaria, filaria, leishmaniasis, kala-azar, and tuberculosis would continue as priority programmes during 11th Plan also. The DBT has launched a collaborative effort with ICMR towards development of novel microbicides targeting HIV I AIDS and other STDs. A novel anti malarial compound has been transferred to Shreya Life Sciences, Mumbai by National Centre for Cell Sciences (NCCS), Pune.

 
< Prev   Next >

Retailing

Kmart Pharmacy has launch of the American Fare Dollar Program, which offers pharmacy customers a choice of 10 over-the-counter (OTC) medications from Kmart's proprietary American Fare brand for only…     Readmore

Image

Outsourcing

The pharmaceutical manufacturers in the United States have attacked the proposed pharma policy of India saying that it would contravene the stated goal of liberalizing the sector, and sought some…     Readmore

Image

Homeopathy

The Homeopatic manufacturing units must fulfill the conditions stated by the government of India under 67-G     Readmore

FDA

Invitrogen Corporation, a provider of essential life science technologies for research, production and diagnostics,  has received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its SPOT-Light(R) HER2…     Readmore

Biotechnology

Attractive incentives and tax soaps offered by the Malaysian government for the biotech and research based companies is luring some major Indian pharmaceutical players to set up units in…     Readmore

Nanotechnology

The UK Royal Commission has issued a report on the spread of nanomaterials, stating that “urgent action [is] needed on testing and regulation”. In its report the Commission found…     Readmore

Packaging

Bilcare Research has launched a product to help check the menace of counterfeit drugs. The product has a label with a unique bar code made out of nanotechnology and…     Readmore